- Home
- SGHT
SGHT
Sight Sciences Inc.
as 11-21-2024 4:00pm EST
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 304.4M | IPO Year: | 2021 |
| Target Price: | $6.80 | AVG Volume (30 days): | 264.4K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.58 - $8.45 | Next Earning Date: | 11-07-2024 |
| Revenue: | $79,543,000 | Revenue Growth: | -3.99% |
| Revenue Growth (this year): | 3.06% | Revenue Growth (next year): | 10.33% |
Stock Insider Trading Activity of Sight Sciences Inc. (SGHT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Link Matthew | SGHT | Chief Commercial Officer | Oct 18 '24 | Sell | $5.79 | 42,318 | $244,900.88 | 685,381 | |
| Link Matthew | SGHT | Chief Commercial Officer | Oct 16 '24 | Sell | $5.87 | 41,704 | $244,878.10 | 685,381 | |
| Badawi David | SGHT | Chief Technology Officer | Oct 2 '24 | Sell | $5.99 | 3,167 | $18,957.66 | 1,756,481 | |
| Badawi Paul | SGHT | President and CEO | Oct 2 '24 | Sell | $5.99 | 12,727 | $76,183.82 | 5,725,433 | |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Oct 1 '24 | Sell | $6.08 | 4,878 | $29,658.24 | 158,687 | |
| Bauerlein Alison | SGHT | Chief Financial Officer | Oct 1 '24 | Sell | $6.08 | 10,130 | $61,590.40 | 392,555 | |
| Park Sam Boong | SGHT | Chief Operating Officer | Oct 1 '24 | Sell | $6.08 | 3,403 | $20,690.24 | 254,826 |
Latest Sight Sciences Inc. News
SGHT Breaking Stock News: Dive into SGHT Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Yahoo Finance
4 days ago
Inside a $400 billion bet on the brain-computer interface revolution
TipRanks
10 days ago
Sight Sciences price target lowered to $5 from $7 at Morgan Stanley
Simply Wall St.
13 days ago
Sight Sciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
14 days ago
Sight Sciences Inc (SGHT) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...
Zacks
14 days ago
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
14 days ago
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance
GlobeNewswire
14 days ago
Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations
Compare SGHT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGHT Sight Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.